CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV

Win Min Han1*, Tanakorn Apornpong1, Stephen J. Kerr1,2, Akarin Hiransutthikul1, Sivaporn Gatechompol1, Tanya Do1, Kiat Ruxrungtham1,2 and Anchalee Avihingsanon1,2

Abstract

Background: Immune restoration is often incomplete after ART in HIV patients, both quantitatively and qualitatively. We studied the incidence and probability of CD4/CD8 normalization in an adult Thai HIV cohort and explored the predictive value of the ratio for developing of non-AIDS defining events (NAEs).

Methods: We analyzed data from HIV-infected Thai adults between 1996 and 2017 in the HIV-NAT 006 prospective long-term cohort in Bangkok, Thailand. Normalization was defined as CD4/CD8 ratio ≥ 1 on two consecutive visits, and normalization probability was calculated using the Kaplan–Meier method. NAEs were a composite endpoint including cardiovascular or cerebrovascular diseases, chronic kidney diseases, non-AIDS defining malignancies and death. Multivariate Cox regression was used to evaluate demographic, disease and treatment characteristics associated with CD4/CD8 ratio normalization and NAEs.

Results: A total of 800 ART-naïve patients with baseline CD4/CD8 ratio of < 0.8 who started combination ART, and had sustained virological suppression were enrolled. Participants were on ART for a median of 8.9 years and virologically suppressed for 6.1 years. The probabilities of CD4/CD8 normalization at 2, 5 and 10 years after virological suppression were 5.1%, 18.6% and 39.1%, respectively. Factors associated with normalization in multivariate analysis were female sex (hazard ratio [HR]: 2.47, 95% CI 1.71–3.56, p < 0.001) and baseline CD4 counts ≥ 350 cells/mm³ (HR: 3.62, 95% CI 2.36–5.55), p < 0.001) vs. < 200 cells/mm³ as reference. The second analysis explored the predictive value of CD4/CD8 ratio for NAEs. Older age (HR: 1.09, 95% CI 1.05–1.13, p < 0.01) and current CD4/CD8 ratio < 0.3 (HR: 3.02, 95% CI 1.27–7.21, p = 0.01) or between 0.3 and 0.45 (HR: 2.03, 95% CI 1.03–3.98, p = 0.04) vs. > 0.45 were independently associated with higher risk of progression to NAEs in the multivariate analysis.

Conclusions: Our findings showed that complete immune recovery is uncommon in an Asian setting and earlier ART initiation at higher CD4 counts may have increased the ratio sooner. The findings demonstrate the use of CD4/CD8 ratio as a prognostic marker for clinical progression of NAEs.

Trial registration HIV-NAT 006 cohort, clinical trial number: NCT00411983

Keywords: CD4/CD8 ratio, Immune restoration, Non-AIDS events, Long-term virological suppression, Asia

*Correspondence: win.m@hivnat.org

1 HIV-NAT, The Thai Red Cross AIDS Research Center, 104 Ratchadamri Rd., Pathumwan, Bangkok 10330, Thailand

Full list of author information is available at the end of the article

All authors belongs to HIV-NAT 006 team.
Background

Survival of HIV-infected individuals has significantly improved with the introduction of combination antiretroviral therapy (cART). Nowadays, since antiretrovirals (ARVs) are initiated in earlier stages of infection, HIV-associated illnesses or complications of acquired immunodeficiency syndrome (AIDS) are less frequently observed in most HIV-infected individuals [1]. Despite low risks of AIDS in many patients who are treated with cART, immune recovery or restoration is rarely achieved [2, 3]. The incidence of several serious non-AIDS defining events (NAEs) including cardiovascular disease, cerebrovascular disease, renal disease and non-ADIS-related cancers have risen as longevity has increased among PLHIV [4]. Lifestyle factors and aging play a role, but the impact of HIV infection and associated chronic inflammatory states on the incidence of these NAEs is still not fully understood.

Chronic inflammation includes persistent ongoing immune activation, bacterial translocation caused by injured mucosa-associated lymphoid tissue, asymptomatic replication of HIV itself and co-pathogens such as cytomegalovirus infection. These conditions lead to immune activation, and hence potentially increase the risk for all-cause mortality in HIV patients [5–8]. The ratio of CD4+ T cells to CD8+ T cells (CD4/CD8 ratio) has been used as a surrogate marker of immunosenescence in both the general population [9, 10] and PLHIV [11]. Additionally, the CD4/CD8 ratio has shown an independent association with NAEs and mortality in people living with HIV (PLHIV) whereas CD4 counts alone do not predict the risk of NAEs [12, 13]. Studies have reported the ratio remains low, with a slow rate of recovery in a substantial proportion of patients, including those with adequate CD4+ T cell count recovery, over years of cART [12, 14]. The clinical significance of this ongoing immune dysfunction needs further exploration.

The majority of previous published studies exploring associations with CD4/CD8 ratios and their prognostic value for predicting NAE have been from Western countries, and evidence to inform an association in HIV-infected Asians is still limited. A study comparing Asian and Caucasian cohorts has shown that the baseline CD4/CD8 ratio before cART initiation was significantly lower in Asians but there were no differences in the odds of achieving the ratio value of > 1 between two cohorts [15].

In this study, we aimed to firstly evaluate the incidence and probability of CD4/CD8 normalization and to explore factors associated with normalization among patients from a Thai HIV cohort with sustained virologic suppression and long-term follow-up. Secondly, we explored the value of CD4/CD8 ratio in predicting NAEs including cardiovascular or cerebrovascular diseases, kidney diseases, non-AIDS malignancies and deaths.

Methods

Study design and population

This is a prospective study in an ongoing HIV Thai adult cohort (HIV-NAT 006 cohort, clinical trial number: NCT00411983). The details of this cohort have previously been described [16–18]. Participants were eligible for inclusion in this analysis if they achieved and maintained suppressed viremia at HIV-RNA<50 copies/mL after starting cART. Once a participant had detectable viral load after achieving suppression, follow-up for that participant was censored. All patients had regular clinic visits where medical history, including the occurrence of NAEs was documented.

Definition of endpoints

The normalization of CD4/CD8 ratio, defined as two consecutive values ratios ≥ 1 [19], was the primary endpoint of the initial analysis. For the second analysis, we defined NAEs as cardiovascular or cerebrovascular diseases (including coronary artery diseases, myocardial ischemia, cerebral artery occlusion and stroke), chronic kidney diseases (defined as confirmed estimated glomerular filtration rate < 60 mL/min with Modification of Diet in Renal Disease MDRD formula), non-AIDS defining malignancies and deaths (excluding 1 death from heroin overdose, 1 unknown cause of death, 3 suicide cases).

Statistical analysis

Firstly, the probabilities of CD4/CD8 ratio normalization and associated factors were identified. Baseline for CD4/CD8 normalization analysis was the first of two consecutive virological suppressions after initiating cART. The normalization incidence rate was calculated by dividing the number of normalization events by total person-years of follow-up (PYFU) after achieving viral suppression. The Kaplan–Meier method was used to assess independent predictors associated with a normalized CD4/CD8 ratio. Baseline covariates modelled were age, sex, mode of HIV transmission, HIV-RNA levels, CD4 and CD8 cell counts, Centers for Disease Control and Prevention (CDC) staging, hepatitis B surface antigen (HBsAg), anti-hepatitis-C antibody (anti-HCV ab).

Secondly, the incidence rate of NAEs was analyzed as a composite endpoint by combining deaths and other NAE in time to event models. CD4/CD8 ratio was fitted as categories with cutoff values of <0.30, 0.30–0.45 and >0.45 [11, 12], for the interests of applicability in clinical practice. A value of CD4/CD8 ratio < 0.4 showed the best cutoff to predict NAEs [11] and to link the association with different T-cell activation markers [2]. In these models,
NAEs or deaths were modelled as a first event; patients not reaching the endpoint were censored at their most recent clinic visit. Time-updated covariates modelled included were age, body mass index (BMI) and tuberculosis infection. Diabetes mellitus was defined by two consecutive values of fasting blood glucose \( \geq 126 \) mg/dL or initiation of anti-diabetic medications. Covariates in univariate analysis with \( p \) value < 0.15 were included in the multivariate model.

**Results**

**CD4/CD8 ratio normalization**

After excluding participants treated with cART before the enrollment into the 006 cohort and who did not have baseline CD4/CD8 ratio measurements, 1236 participants were evaluated. We then excluded the patients who had baseline CD4/CD8 ratio \( \geq 0.8 \) and those who commenced on mono or dual ART regimens which may have biased ratio recovery times (Fig. 1). Finally, a total of 800 HIV-infected adults, with 67% male, median age of 32.3 (interquartile range, IQR, 27.4–37.5) years and median baseline HIV-RNA level of 4.8 (IQR, 4.39–5.24) \( \log_{10} \) copies/mL, achieved viral suppression and were included in the analysis. Of 800 participants, most were heterosexual (54%) and the rest were homosexual or bisexual (35%) injecting drug users (0.8%) and others (11%), with a median duration of 7 (IQR, 4–35) months to achieve the first virological suppression. Median duration of cART over follow-up was 8.9 (IQR, 5.2–13.7) years. Most participants (47%) achieved virological suppression within 6 months and their median duration of suppression was 6.08 (IQR, 2.97–10.75) years (Table 1). Participants who achieved virological suppression within 6 months had higher pre-cART CD4/CD8 ratio (0.23 vs. 0.21, \( p = 0.04 \)) and lower pre-cART HIV RNA level (4.72 \( \log_{10} \) vs. 4.85 \( \log_{10} \) copies/mL, \( p < 0.005 \)), compared to those achieving virological suppression later. There were no differences in pre-cART CD4, CD8 counts or CDC staging between the two groups. Overall baseline CD4/CD8 ratio before cART initiation was 0.22 (IQR, 0.12–0.32) and median CD4/CD8 ratio at confirmed first time of virological suppression was 0.42 (IQR: 0.27–0.56).

The overall incidence rate of CD4/CD8 ratio normalization was 4.38 per 100 PYFU (95% confidence interval [CI] 3.81–5.04) with 4289 PYFU. With Kaplan–Meier estimation methods, we found that the probabilities of normalization at 2, 5 and 10 years after virological suppression were 5.1%, 18.6% and 39.1%, respectively (Figs. 2 and 3). Thirty-six percent of those who achieved normalization had pre-cART CD4 counts \( \leq 200 \) cell counts, compared to 52% of patients who failed to achieve normalization (\( p < 0.001 \)). Median pre-cART CD4/CD8 ratios for participants achieving normalization and the non-achiever group were 0.20 (IQR, 0.10–0.30) and 0.28 (IQR, 0.18–0.39), respectively. Of note, the duration of virological suppression was longer among the patients who achieved the normalization target than the non-normalization group (10.8 years [IQR: 7.5–12.7] vs. 4.9 years, [IQR: 2.3–9.1], \( p < 0.001 \)). However, there was no significant difference in the time to first virological suppression between patients who achieved normalization and who did not have normal ratios (\( p = 0.243 \)). Additionally, there was significant difference in CD4/CD8 ratio at first virological suppression between two groups, with median value of 0.38 (IQR: 0.24–0.5) in patients without CD4/CD8 normalization and 0.54 (0.42–0.69) in the group achieving normalization (\( p < 0.001 \)).

In multivariate analysis (Table 2), after adjusting for CDC category, months since starting cART to first virological suppression, HBsAg status and baseline cART
regimen, factors independently associated with CD4/CD8 ratio normalization were female sex (hazard ratio [HR]: 2.47, 95% CI 1.71–3.56, p < 0.001) and baseline CD4 counts ≥350 cells/mm³ (HR: 3.62, 95% CI 2.36–5.55, p < 0.001) or between 200 and 350 cells/mm³ (HR: 1.95, 95% CI 1.40–2.72, p < 0.001) vs. < 200 cells/mm³ as reference. The interaction between age and CD4/CD8 ratio was tested in the model by using the ratio as continuous, and grouped in categories that matched the analysis. However, no interactions were found.

Non-AIDS defining events

We next explored the associations of CD4/CD8 ratio and NAEs in the second part of our analysis. A total of 123 NAEs occurred in a total of 4071 person-years of follow-up. Among them, 108 participants developed chronic kidney disease, 5 developed cardiovascular or cerebrovascular events, 12 developed non-AIDS malignancies and 15 participants died. Among them, 16 patients had more than one of the events mentioned. Overall incidence of NAEs as first events was 3.02 (2.53–3.61) per 100 person-years of follow-up (100 PYS). The incidence

Table 1  Patient characteristics

|                          | N     | Descriptive, median (IQR) or n (%) | Not achieved CD4/CD8 ratio < 1 (N = 606) | Achieved CD4/CD8 ratio ≥ 1 (N = 194) | p-value |
|--------------------------|-------|------------------------------------|----------------------------------------|--------------------------------------|---------|
| Gender, n (%)            | 800   | 533 (66.63)                        | 439 (72.44)                            | 94 (48.45)                           | <0.001  |
| Male                     |       |                                    |                                        |                                      |         |
| Female                   |       | 267 (33.38)                        | 167 (27.56)                            | 100 (51.55)                          |         |
| Age at start ARV         | 800   | 32.3 (27.4–37.5)                   | 31.8 (26.7–37.1)                       | 33.7 (28.6–38.5)                     | 0.006   |
| Pre-cART HIV-RNA level   | 800   | 4.8 (3.9–5.24)                     | 4.83 (4.44–5.25)                       | 4.67 (4.18–5.2)                      | 0.003   |
| Pre-cART CD4 count       | 799   | 206 (102–291)                      | 193 (80–282)                           | 229 (170–316)                        | 0.0001  |
| Pre-cART CD8 count       | 769   | 853 (611–1190)                     | 890 (616–1219)                         | 818 (596–1109)                       | 0.16    |
| Pre-ART CD4/CD8 ratio    | 769   | 0.22 (0.12–0.32)                   | 0.20 (0.10–0.30)                       | 0.28 (0.18–0.39)                     | <0.001  |
| CDC grading, n (%)       | 790   |                                    |                                        |                                      | 0.045   |
| A                        |       | 466 (58.99)                        | 338 (56.71)                            | 128 (65.98)                          |         |
| B                        |       | 223 (28.23)                        | 174 (29.19)                            | 49 (25.26)                           |         |
| C                        |       | 101 (12.78)                        | 84 (14.09)                             | 17 (8.76)                            |         |
| Route of transmission, n (%) | 800 |                                    |                                        |                                      | 0.002   |
| Heterosexual             |       | 433 (54.13)                        | 305 (50.33)                            | 128 (65.98)                          |         |
| MSM/bisexual             |       | 280 (35)                           | 233 (38.45)                            | 47 (24.23)                           |         |
| IDU                      |       | 6 (0.75)                           | 5 (0.83)                               | 1 (0.52)                             |         |
| Others                   |       | 4 (0.5)                            | 4 (0.66)                               | 0 (0)                                |         |
| Unknown                  |       | 77 (9.63)                          | 59 (9.74)                              | 18 (9.28)                            |         |
| Months since cART start to first virological suppression | 7 (4–35) | 7 (3–34) | 9 (4–38) | 0.51 |
| Duration of cART (years) | 800   | 8.9 (5.2–13.7)                     | 7.0 (4.2–12.1)                         | 13.5 (9.3–16.7)                      | <0.001  |
| Duration of viral suppression (years) | 800 | 6.08 (2.97–10.75) | 4.91 (2.26–9.12) | 10.77 (7.49–12.74) | <0.001 |
| CD4/CD8 ratio at first viral suppression, median (IQR) | 800 | 0.42 (0.27–0.56) | 0.38 (0.24–0.5) | 0.54 (0.42–0.69) | <0.001 |
| CD4/CD8 ratio at first viral suppression, n (%) | 800 | <0.001 |
| <0.3                     |       | 224 (28.00)                        | 209 (34.49)                            | 15 (7.73)                            |         |
| 0.30–0.45                |       | 228 (28.50)                        | 182 (30.03)                            | 46 (23.71)                           |         |
| >0.45                    |       | 348 (43.50)                        | 215 (35.48)                            | 133 (68.56)                          |         |
| Positive HBsAg, n (%)    | 784   | 130/784 (16.58)                    | 108/592 (18.24)                        | 22/192 (11.46)                       | 0.028   |
| Positive anti-HCV Ab, n (%) | 796 | 66/796 (8.29) | 50/602 (8.31) | 16/194 (8.25) | 0.980 |
| Baseline ARV regimen, n (%) | 800 | <0.001 |
| PI-based regimen         |       | 272 (34)                           | 178 (29.37)                            | 94 (48.45)                           |         |
| NNRTI-based regimen      |       | 509 (63.63)                        | 411 (67.82)                            | 98 (50.52)                           |         |
| INSTI-based regimen      |       | 19 (2.38)                          | 17 (2.81)                              | 2 (1.03)                             |         |

Descriptive data are n (%) or median (IQR interquartile range), ART antiretroviral therapy, MSM men who have sex with men, IDU injecting drug users, ARV antiretroviral drugs, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, INSTI integrase strand transfer inhibitors
rates of non-AIDS composite events were significantly different between the cutoffs for CD4/CD8 ratio, with 11.42 per 100 PYS (95% CI 7.45–17.52) for current CD4/CD8 ratio < 0.3 and 2.23 per 100 PYS (1.77–2.81) for ratio > 0.45 (Table 3).

Univariate and multivariate analyses of the risk factors associated with composite endpoint of NAEs are summarized in Table 4. Older age, MSM or bisexual (vs. heterosexual), time updated CD4/CD8 ratio (<0.3 and 0.3–0.45 vs. >0.45), diabetes mellitus (DM), baseline protease inhibitors-based regimen and cART initiation after calendar year 2007 (vs. before 2007) were associated with higher chances of non-AIDS composite end point in univariate analysis. However, after adjusting the potential cofounders from the univariate analysis, older age (HR: 1.09, 95% CI 1.05–1.13, p < 0.01) and CD4/CD8 ratio (HR: 3.02, 95% CI 1.27–7.21, p = 0.01) for ratio <0.3 and between 0.3 and 0.45 (HR: 2.03, 95% CI 1.03–3.98, p = 0.04) vs. >0.45 were independently associated with higher risks of progression to NAEs in the multivariate analysis.

### Table 2 Factors associated with normalisation of CD4/CD8 (ratio ≥ 1)

| Variables                      | Univariate HR (95% CI)   | p-value | Multivariate HR (95% CI) | p-value |
|--------------------------------|--------------------------|---------|--------------------------|---------|
| Gender                         |                          |         |                          |         |
| Male                           | Ref                      |         |                          |         |
| Female                         | 1.99 (1.5–2.64)          | <0.001  | 2.47 (1.71–3.56)         | <0.001  |
| Age, (per year older)          | 1.001 (0.98–1.02)        | 0.906   |                         |         |
| Body mass index (BMI, kg/m²)   |                          |         |                          |         |
| < 25                           | 1.11 (0.75–1.64)         | 0.606   |                         |         |
| ≥ 25                           | Ref                      |         |                          |         |
| Pre–cART HIV-RNA level (log₁₀ copies/mL) | 0.79 (0.65–0.96) | 0.017   |                         |         |
| Pre-cART CD4 count (per 100 cell/mm³ increased) | 1.40 (1.28–1.54) | <0.001  |                         |         |
| Pre-cART CD4 count (cells/mm³) |                          |         |                          |         |
| 0–200                          | Ref                      |         |                          |         |
| 201–350                        | 2.05 (1.5–2.81)          | <0.001  | 1.95 (1.4–2.72)         | <0.001  |
| ≥ 351                          | 3.47 (2.31–5.2)          | <0.001  | 3.62 (2.36–5.55)        | <0.001  |
| Pre-cART CD8 count (per 50 cell/mm³ increase) | 0.99 (0.97–1.004) | 0.139   |                         |         |
| CDC grading                    |                          |         |                          |         |
| A, or B                        | 1.81 (1.1–2.99)          | 0.019   | 1.2 (0.71–2.02)         | 0.503   |
| C                              | Ref                      |         |                         |         |
| Months since ART start to first virological suppression |        |         |                          |         |
| < 6 months                     | Ref                      |         |                          |         |
| 6–12 months                    | 0.48 (0.22–1.06)         | 0.07    | 1.30 (0.84–2.02)        | 0.24    |
| ≥ 12 months                    | 1.14 (0.79–1.64)         | 0.49    | 1.49 (0.89–2.51)        | 0.13    |
| HBsAg status                   |                          |         |                          |         |
| Negative                       | 1.62 (1.04–2.52)         | 0.04    | 1.26 (0.79–2.01)        | 0.33    |
| Positive                       | Ref                      |         |                          |         |
| Anti-HCV Ab status             |                          |         |                          |         |
| Negative                       | 1.08 (0.65–1.81)         | 0.76    |                         |         |
| Positive                       | Ref                      |         |                          |         |
| Baseline ARV regimen           |                          |         |                          |         |
| NNRTI based                    | Ref                      |         |                          |         |
| PI based                       | 1.50 (1.13–1.99)         | 0.01    | 1.35 (0.99–1.82)        | 0.051   |
| INSTI based                    | 2.01 (0.49–8.27)         | 0.33    | 1.60 (0.38–6.70)        | 0.52    |
| cART by calendar year          |                          |         |                          |         |
| < 2007                         | Ref                      |         |                          |         |
| ≥ 2007                         | 0.85 (0.61–1.2)          | 0.37    |                         |         |

IQR interquartile range, ART antiretroviral therapy, MSM men who have sex with men, IDU injecting drug users, ARV antiretroviral drugs, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, INSTI integrase strand transfer inhibitors

Significant p-values are in italics (p < 0.001)
was confirmed at 2 consecutive visits. Using this method, 48 patients met criteria for CKD, and we found significantly elevated risks of NAE in multivariate models: HR 3.29 (95% CI 1.66–6.50; \(p=0.001\)) for current CD4/CD8 ratio < 0.3) and HR 2.46 (95% CI 1.44–4.20; \(p=0.001\)) for those with ratios between 0.3 and 0.45, vs. > 0.45 as the reference group.

**Discussion**

In our cohort with median duration cART of 8.9 years and median duration of virological suppression of 6.1 years, the probability of achieving CD4/CD8 normalization at 5 and 10 years was 19% and 39% respectively. These Kaplan–Meier probabilities are consistent with our incidence rate of approximately 4% per year. Our data confirmed the previous few available data demonstrating the prolonged duration of recovery to normal CD4/CD8 ratio among PLHIV with suppressive cART, with a median of 10 years to reach normalization target [12]. This study also demonstrated that low ratio was a higher risk for clinical progression of NAEs. This can be translated into that persistent disparity between CD4 and CD8 cell counts, even with CD4 recovery after cART, could be a critical marker for evaluating the prognosis of long-term virologically suppressed PLHIV. Our patients had a relatively lower incidence of CD4/CD8 ratio normalization compared to an Italian cohort. The Italian cohort that included only patients with undetectable HIV viral load (HIV-RNA level < 80 copies/mL) after cART initiation, showed 29% achieved ratio normalization by 5 years whereas it was 19% by 5 years from our study [12]. However, the baseline median CD4/CD8 ratio and median nadir CD4 count in the Italian cohort were higher than those of our Thai cohort (0.39 vs. 0.22, and 378 vs. 206 cells/mm³, respectively). Our study showed that higher chances of normalization were associated with higher baseline CD4 counts (> 350 cells/mm³). This is consistent with previous studies suggesting baseline CD4 counts < 200 cells/mm³ was an unfavorable predictor towards CD4/CD8 ratio normalization [3, 12], and that low CD4 T-cell counts at baseline before cART are associated with incomplete immune response even after years of viral suppression [20]. Moreover, improvement of CD4/CD8 ratio was seen in both normalization and non-normalization groups after having suppressed viremia, compared to baseline values before cART initiation. This suggests that current ART guidelines recommending initiation of cART treatment with higher CD4 cell counts will have benefits in increasing the number of participants achieved higher CD4/CD8 ratios earlier.

The literature is conflicting regarding the use of CD4/CD8 ratio as a surrogate marker to describe immune dysfunction and to predict the progression towards NAEs...
### Table 4 Factors associated with composite end point

| Variables                                                                 | Univariate model |                                                                 | Multivariate model |                                                                 |
|--------------------------------------------------------------------------|------------------|-----------------------------------------------------------------|--------------------|-----------------------------------------------------------------|
|                                                                          | HR               | 95% CI              | p-value            | HR                 | 95% CI              | p-value            |
| Gender                                                                   |                  |                    |                   |                    |                    |                   |
| Male                                                                    | Ref              |                    |                   | Ref                |                    |                   |
| Female                                                                   | 1.09             | (0.75–1.58)         | 0.65              | 1.09               | (1.05–1.13)         | < 0.001            |
| Age, year                                                               | 1.07             | (1.04–1.09)         | < 0.001           | 1.09               | (1.05–1.13)         | < 0.001            |
| BMI, kg/m²                                                               |                  |                    |                   |                    |                    |                   |
| < 25                                                                    | Ref              |                    |                   | Ref                |                    |                   |
| ≥ 25                                                                    | 1.68             | (0.89–3.16)         | 0.11              | 1.42               | (0.73–2.76)         | 0.30               |
| Route of transmission                                                   |                  |                    |                   |                    |                    |                   |
| Heterosexual                                                             | Ref              |                    |                   | Ref                |                    |                   |
| MSM/bisexual                                                             | 0.54             | (0.35–0.82)         | 0.004             | 1.74               | (0.95–3.21)         | 0.07               |
| IDU/others/unknown                                                       | 0.66             | (0.33–1.30)         | 0.23              | 1.06               | (0.32–3.53)         | 0.93               |
| Ever smoking                                                             | 0.82             | (0.56–1.20)         | 0.31              |                    |                    |                   |
| Ever alcohol drinking                                                    | 0.82             | (0.38–1.77)         | 0.62              |                    |                    |                   |
| Baseline HIV-RNA level (log_{10} copies/mL)                             | 1.19             | (0.92–1.54)         | 0.19              |                    |                    |                   |
| Baseline CDC grading                                                    |                  |                    |                   |                    |                    |                   |
| Stage A or B                                                             | Ref              |                    |                   | Ref                |                    |                   |
| Stage C                                                                  | 1.03             | (0.61–1.74)         | 0.92              |                    |                    |                   |
| Tuberculosis infection                                                  |                  |                    |                   |                    |                    |                   |
| No                                                                      | 1.24             | (0.17–8.93)         | 0.83              |                    |                    |                   |
| Yes                                                                     |                  |                    |                   |                    |                    |                   |
| Time since ART initiation to first viral suppression                    |                  |                    | 0.057             |                    |                    |                   |
| < 6 months                                                              | Ref              |                    |                   | Ref                |                    |                   |
| 6–12 months                                                             | 0.48             | (0.22–1.06)         | 0.07              |                    |                    |                   |
| ≥ 12 months                                                             | 1.14             | (0.79–1.64)         | 0.49              |                    |                    |                   |
| Current CD4 counts per 100 increased                                    | 0.93             | (0.85–1.02)         | 0.12              |                    |                    |                   |
| Current CD4/CD8                                                          |                  |                    |                   |                    |                    |                   |
| < 0.3                                                                  | 3.10             | (1.87–5.14)         | < 0.001           | 3.02               | (1.27–7.21)         | 0.001              |
| 0.30–0.45                                                               | 1.76             | (1.13–2.75)         | 0.01              | 2.03               | (1.03–3.98)         | 0.04               |
| > 0.45                                                                  | Ref              |                    |                   | Ref                |                    |                   |
| Diabetes mellitus                                                        | 2.27             | (1.52–3.39)         | < 0.001           | 3.02               | (0.06–163.26)       | 0.59               |
| HBs Ag status                                                           |                  |                    |                   |                    |                    |                   |
| Negative                                                                | Ref              |                    |                   | Ref                |                    |                   |
| Positive                                                                | 0.69             | (0.40–1.18)         | 0.17              |                    |                    |                   |
| Anti-HCV Ab status                                                      |                  |                    |                   |                    |                    |                   |
| Negative                                                                | Ref              |                    |                   | Ref                |                    |                   |
| Positive                                                                | 1.04             | (0.54–1.98)         | 0.92              |                    |                    |                   |
| Baseline ARV regimen                                                     |                  |                    |                   |                    |                    |                   |
| NNRTI-based                                                              | Ref              |                    |                   | Ref                |                    |                   |
| PI-based                                                                | 1.55             | (1.09–2.22)         | 0.015             | 1.09               | (0.6–1.99)          | 0.77               |
| cART by calendar year                                                   |                  |                    |                   |                    |                    |                   |
| < 2007                                                                  | Ref              |                    |                   | Ref                |                    |                   |
| ≥ 2007                                                                  | 0.40             | (0.27–0.61)         | < 0.001           | 1.29               | (0.7–2.36)          | 0.42               |

Significant p-values are in italics

IQR: interquartile range, BMI: body mass index, MSM: men who have sex with men, IDU: injecting drug users, ARV: antiretroviral drugs, ART: antiretroviral therapy, NNRTI: non-nucleoside reverse transcriptase inhibitor, PI: protease inhibitor, INSTI: integrase strand transfer inhibitors

* Time-updated variables include age, BMI and tuberculosis infections
and mortality [12, 13, 21]. A report from Mussini et al. [12] suggested the predictive value of CD4/CD8 ratio for clinical progression of severe NAEs and deaths among patients with prolonged cART treatment in a large Italian cohort, with the same cutoff values of the ratio used in our study. In contrast, in a large collaborative study of European and North American cohorts failed to show a link between low CD4/CD8 ratio and non-AIDS related mortality among virologically suppressed patients on cART [21]. Of note, the study showed low ratio and high CD8 counts were associated with AIDS-related mortalities. We sought to carry out an additional analysis to explore whether CD4/CD8 ratio has an association with development of NAEs. Our case definition of NAEs was similar to the ones used in previous studies, which included cardiovascular and cerebrovascular diseases, non-AIDS defining cancers, kidney diseases and deaths [12, 13]. The incidence rates of composite non-AIDS endpoints were significantly different among categories with different CD4/CD8 ratio cutoff values in our study. Patients with low CD4/CD8 ratio had higher incidence rates of NAEs than those with higher ratios. In multivariate analysis, we also found the independent associations of low CD4/CD8 ratio with composite end point or deaths after adjusting for potential confounders that were significant in the univariate analysis.

Previous reports have also suggested the association of CD4/CD8 ratio in T-cell activation or senescence [22, 23]. A plausible explanation associations with NAEs is that low CD4/CD8 ratio could be a marker of ongoing immune dysfunction among prolonged virologically suppressed HIV patients on stable cART since immune activation is been associated with clinical events and mortality in PLHIV [24].

One of the strengths of our study is the prolonged follow-up time with a median of 8.9 (IQR, 5.2–13.7) years of cART treatment. Our participants were taking cART with prolonged duration of virological suppression of 6.1 (IQR, 3–10.8) years. Another strength of our study is that we evaluated the probabilities of normalization among virologically suppressed participants up to 10 years. This is relatively longer than other studies which showed the normalization probabilities just up to 2 years [3] and 5 years [12], respectively.

Several important limitations in this study should be acknowledged. First, we could not provide the association of low CD4/CD8 ratio with each particular non-AIDS incident due to low numbers of events in each category. Second, we could not include some potential factors that have previously suggested may have influences on immune activation or persistent inflammation such as cytomegalovirus (CMV) co-infection [25, 26] in our study analysis. Third, our study population could be considered low risk, since they started cART, and maintained good adherence and virological suppression. Nevertheless, this also allowed us to assess CD4/CD8 ratio recovery without the confounding effect of viremia. Fourth, the study was a retrospective analysis from a prospective cohort. The conclusion for causal inference between low CD4/CD8 ratio and NAEs is therefore low due to the observational nature of the cohort. Lastly, although CD4/CD8 ratios may be a useful marker, there is no known strategy apart from taking cART to improve ratios that are low. Further analyses should explore whether newer therapies for HIV treatment such integrase strand inhibitors or monoclonal antibodies have additional impact on CD4/CD8 ratio recovery.

Conclusions
Probabilities of immune recovery among patients on cART is relatively low in our cohort, suggesting the ongoing immune dysfunctions even after years of treatment. Patients with low baseline CD4 counts were less likely to achieve ratio normalization. Earlier ART initiation may result in increased normalization rates. We also sought to use multiple NAEs as a composite endpoint to determine its association with the ratio. The finding of low ratio with the linkage to NAEs highlights the potential use of CD4/CD8 ratios as a marker for the clinical progression of non-communicable diseases and mortality among PLHIV with prolonged suppression of viremia.

Acknowledgements
We thank to the study participants and all team members from the HIV-NAT 006 cohort.

Competing interests
KR has received the Senior Research Scholar from Thailand Research Fund (TRF), and has received honoraria or consultation fees from Merck, Roche, Jensen-Cilag, Tibotec, Mylan and GPO (Governmental pharmaceutical organization, Thailand). He also has participated in company sponsored speaker’s bureaus for Abbott, Gilead, Bristol-Myers Squibb, Merck, Roche, Jensen-Cilag, GlaxoSmithKline, and GPO (Governmental pharmaceutical organization). AA participated in a company sponsored speaker’s bureau from Jensen-Cilag, Gilead and Bristol-Meyer Squibb. The rest of the authors declare that they have no competing interests.

Availability of data and materials
Data were extracted from the electronic database of HIV-NAT 006 cohort.
References

1. Low A, Gavrilidis G, Larke N, B-Lajoie MR, Drouin O, Stover J, et al. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(12):1595–603.

2. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.

3. Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, et al. Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. PLoS ONE. 2013;8(10):e77665.

4. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al. Determinants of a low CD4/CD8 ratio in HIV-1-infected individuals despite long-term viral suppression. Clin Infect Dis. 2016;62(10):1297–303.

5. Petoumenos K, Choi JY, Huy J, Kiertiburanakul S, Ng OT, Boyd M, et al. CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy. Antivir Ther. 2017;22(8):659–68.

6. Putchareon O, Wattanachanya L, Sophonphphan J, Siwamogatham S, Sapsrisavat V, Gatechompol S, et al. New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes. AIDS. 2017;31(11):1535–43.

7. Durier N, Ananworanich J, Apompong T, Ubolayom S, Kerr SJ, Mahanantthan A, et al. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality. Clin Infect Dis. 2013;57(1):147–55.

8. Edwards-Jackson N, Kerr S, Teiu H, Ananworanich J, Hammer S, Ruhrungtham K, et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med. 2011;12(8):510–5.

9. Tinago W, Coghlan E, Macken A, McAndrews J, Doak B, Prior-Fuller C, et al. Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+ T-cell ratio: effect of naive and memory T-cell subsets. PLoS ONE. 2014;9(5):e97011.

10. Falster K, Petoumenos K, Chuah J, Mijch A, Muhall B, Kelly M, et al. Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. J Acquir Immune Defic Syndr. 2009;50(3):307–13.

11. Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, et al. The CD4/CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: the antiretroviral therapy cohort collaboration (ART-CC). Clin Infect Dis. 2017;65(6):959–66.

12. Serrano-Villar S, Gutierrez C, Vallejo A, Hernandez-Novaoa B, Diaz L, Abad Fernandez M, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect. 2013;66(1):37–67.

13. Sainz T, Serrano-Villar S, Diaz L, Gonzalez Tome MI, et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and exhaustion in treated HIV-infected children and young adults. AIDS. 2013;27(9):1513–6.

14. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect. 2011;203(6):780–90.

15. Barrett L, Stapleton SN, Fudge NJ, Grant MD. Immune resilience in HIV-infected individuals seronegative for cytomegalovirus. AIDS. 2014;28(14):2045–9.

16. Freeman ML, Mudd JC, Shive CL, Younes SA, Panisrahi S, Sieg SF, et al. CD8 T-cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection. Clin Infect Dis. 2016;62(3):392–6.